News | Radiopharmaceuticals and Tracers | June 05, 2019

BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method

Novel technique enables simultaneous production of molybdenum-99 and other isotopes without the need for highly enriched, weapons-grade uranium

BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method

June 5, 2019 – BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for producing radioisotopes for nuclear medicine and medical imaging technologies such as computed tomography (CT) scan and positron emission tomography-computed tomography (PET-CT).

Developed by Alexander Tsechanski, Ph.D., from the BGU Department of Nuclear Engineering, the new technique obviates the need for highly enriched, weapons-grade uranium and a nuclear reactor. Nuclear medicine often necessitates the use of technetium-99m (Tc-99m) as the isotope for imaging, an unstable technetium isotope with a only a six-hour half-life that requires onsite production. In order to produce it in an economically efficient way, currently it requires weapons-grade, highly enriched uranium and a nuclear reactor to generate molybdenum-99 (Mo-99), which decays into technetium-99m (Tc-99m).

The new invention uses the naturally occurring and stable molybdenum-100 (Mo-100) isotope and a linear electron accelerator to generate Mo-99 and Tc-99m1. This process can also simultaneously generate other short-lived radioisotopes such as F-18, O-15, N-13 and C-11 as byproducts for use in PET scans.

BGN Technologies said it is currently looking for partners for further developing and commercializing the technology.

For more information: www.in.bgu.ac.il

Related Radiopharmaceuticals Content

Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes

FDA Clears Path for First Domestic Supply of Tc-99m Isotope

Reference

1. Fedorchenkoa D.V. and Tsechanski A. Photoneutronic aspects of the molybdenum-99 production by means of electron linear accelerators. Nuclear Inst. and Methods in Physics Research B, published online Oct. 23, 2018. https://doi.org/10.1016/j.nimb.2018.10.018


Related Content

News | Radiopharmaceuticals and Tracers

March 27, 2025 — GE HealthCare is announcing the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the 2025 ...

Home March 25, 2025
Home
News | Radiopharmaceuticals and Tracers

April 13, 2023 — A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin ...

Home April 13, 2023
Home
News | Radiopharmaceuticals and Tracers

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Home November 05, 2022
Home
News | Radiopharmaceuticals and Tracers

June 24, 2022 — Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive ...

Home June 24, 2022
Home
News | Radiopharmaceuticals and Tracers

August 2, 2019 — The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) ...

Home August 02, 2019
Home
News | Radiopharmaceuticals and Tracers

July 16, 2019 – NorthStar Medical Radioisotopes LLC announced completion of construction on its 20,000-square-foot ...

Home July 16, 2019
Home
News | Radiopharmaceuticals and Tracers

May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular ...

Home May 17, 2019
Home
News | Radiopharmaceuticals and Tracers | Jeff Zagoudis, Associate Editor

May 10, 2019 — Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in ...

Home May 10, 2019
Home
News | Radiopharmaceuticals and Tracers

October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide ...

Home October 12, 2018
Home
Feature | Radiopharmaceuticals and Tracers | Dave Fornell

February 8, 2018 — The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) recently took ...

Home February 26, 2018
Home
Subscribe Now